netFormulary

North East and North Cumbria
ICS Formulary

back

4 Central nervous system

04-02-01 Second Generation Antipsychotic Drugs

Risperidone

Formulary

Note: risperidone orodispersible tablets should only be used in situations where the plain tablets are unsuitable.

MHRA Drug Safety Update (Nov 2013): Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery

Amisulpride

Formulary

Aripiprazole

Formulary

Approved for schizophrenia in people aged 15 to 17 years in line with NICE.

Approved for moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder NICE.

Aripriprazole 10mg & 15mg orodispersible tablets are approved for doses over 5mg for those patients who have difficulty swallowing.

Aripiprazole 1mg in 1ml oral solution is only for doses of 5mg or less, or when titrating patients on doses of increments of less than 5mg, in patients who have difficulty swallowing tablets.

To be used in accordance with NICE criteria.

Note: Aripiprazole 7.5mg/ml IM Injection is approved for use in rapid tranquilisation in patients with acute psychosis. NTW use only.

MHRA Drug Safety Update (December 2023): Aripiprazole (Abilify and generic brands): risk of pathological gambling

NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years

NICE TA292: Bipolar disorder (children) - aripiprazole

Clozapine

Formulary

First choice in patients with treatment-resistant schizophrenia.

MHRA Drug Safety Alert (Oct 2017): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus

MHRA Drug Safety Update (Aug 2020): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity

North East and North Cumbria ICB - Clozapine supporting guidance for primary care

Lurasidone Latuda^®

Formulary

18.5mg, 37mg and 74mg tablets

Approved for the treatment of schizophrenia in adults and adolescents aged 13 years and over

NTAG - Lurasidone Treatment Appraisal: Decision Summary

Olanzapine

Formulary

Olanzapine orodispersible tablets should only be used in situations where the plain tablets are unsuitable.

Olanzapine orodispersible tablets and injection are also approved for 2nd/3rd- line use in the management of delirium in critical care patients unlicensed indication.

10 mg injection
- for rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
- for delirium at end of life

210mg, 300mg & 405mg powder and solvent for suspension for long-acting injection (as olanzapine embonate monohydrate)
- approved for the treatment of schizophrenia in adults within secure psychiatric services

Quetiapine

Formulary

25mg, 100mg, 150mg 200mg & 300mg tablets

50mg, 200mg, 300mg & 400mg prolonged release tablets
- Prolonged release tablets are approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital.

Quetiapine 20mg/ml Oral Suspension (Rosemont) - CNTW only

Links